PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Journal of Stroke10.5853/jos.2022.030342023251126-131Practical Nomogram Predicting Apixaban or Rivaroxaban Concentrations from Low-Molecular-Weight Heparin Anti-Xa Values: Special Interest in Acute Ischemic Stroke PatientsCharlyne Brakta, Alain Stépanian, Peggy Reiner, Maxime Delrue, Mikaël Mazighi, Emmanuel Curis, Virginie Sigurethttp://j-stroke.org/upload/pdf/jos-2022-03034.pdf, http://j-stroke.org/journal/view.php?doi=10.5853/jos.2022.03034, http://j-stroke.org/upload/pdf/jos-2022-03034.pdf
Thrombosis Research10.1016/j.thromres.2022.05.00520222151-4Low molecular weight heparin anti-Xa assays can identify patients with clinically important apixaban and rivaroxaban drug levelsSiraj Mithoowani, Karen A. Moffat, Akash Gupta, Stephen A. Carlino, Mark A. Crowtherhttps://api.elsevier.com/content/article/PII:S0049384822002584?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0049384822002584?httpAccept=text/plain
International Journal of Laboratory Hematology10.1111/ijlh.136922021441163-167Using a low–molecular weight heparin–calibrated anti–factor Xa assay to assess the concentration of apixaban and rivaroxabanHenrik Horn, Agnes Rasmusson, Lisbeth Söderblom, Rickard E Malmström, Jovan Antovichttps://onlinelibrary.wiley.com/doi/pdf/10.1111/ijlh.13692, https://onlinelibrary.wiley.com/doi/full-xml/10.1111/ijlh.13692, https://onlinelibrary.wiley.com/doi/pdf/10.1111/ijlh.13692
Laboratory Medicine10.1093/labmed/lmac1372022Comparison of Commercial Low Molecular Weight Heparin and Homemade Anti-Xa Calibrators to a Commercial Specific Anti-Xa Calibrator for Plasma Rivaroxaban Quantification by Anti-Xa Oral Anticoagulant Plasma Concentration Chromogenic AssayBita Divsalar, Tahereh Kalantari, Soheila Mohebbi, Ardeshir Bahmanimehr, Amin Shahsavani, Afshin Borhani-Haghighihttps://academic.oup.com/labmed/advance-article-pdf/doi/10.1093/labmed/lmac137/48422729/lmac137.pdf, https://academic.oup.com/labmed/advance-article-pdf/doi/10.1093/labmed/lmac137/48422729/lmac137.pdf
Pathology10.1016/j.pathol.2019.07.0122019517768-769Anti-Xa levels with low molecular weight heparin calibrator can be used to exclude significant apixaban effectJ. Singh, D.M. Ong, A. Wallis, G. Kelsey, H. Tranhttps://api.elsevier.com/content/article/PII:S0031302519303848?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0031302519303848?httpAccept=text/plain
Aterotromboz = Atherothrombosis10.21518/2307-1109-2020-2-96-1042020296-104Chromogenic anti-Xa test: the ratio between heparin activity units and concentration of apixaban and rivaroxabanE. V. Titaeva, A. B. Dobrovolskyhttps://www.aterotromboz.ru/jour/article/viewFile/230/255
Clinical & Laboratory Haematology10.1046/j.1365-2257.2003.00542.x2003255317-319Effect of 3.2 vs. 3.8% sodium citrate concentration on anti-Xa levels for patients on therapeutic low molecular weight heparinS. Payne, K. MacKinnon, M. Keeney, B. Morrow, M. J. Kovacshttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1046%2Fj.1365-2257.2003.00542.x, https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1046%2Fj.1365-2257.2003.00542.x, http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.1365-2257.2003.00542.x/fullpdf
Transfusion and Apheresis Science10.1016/j.transci.2016.06.0052016552212-215Can an anti-Xa assay for low-molecular-weight heparin be used to assess the presence of rivaroxaban?Sean G. Yates, Sabra Smith, William Tharpe, Yu-Min Shen, Ravi Sarodehttps://api.elsevier.com/content/article/PII:S1473050216300672?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1473050216300672?httpAccept=text/plain
Journal of Stroke and Cerebrovascular Diseases10.1053/jscd.2002.126694200211255-62Low molecular weight heparin versus aspirin for acute ischemic stroke: A systematic reviewPhilip Bath, Jo Leonardi-Bee, Fiona Bathhttps://api.elsevier.com/content/article/PII:S1052305702000149?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1052305702000149?httpAccept=text/plain
Respirology10.1111/resp.13699_67201924S223-23DEVELOPMENT AND VALIDATION OF A NOMOGRAM FOR PREDICTING STROKE‐ASSOCIATED PNEUMONIA IN PATIENTS WITH ACUTE ISCHEMIC STROKEhttps://onlinelibrary.wiley.com/doi/pdf/10.1111/resp.13699_67, https://onlinelibrary.wiley.com/doi/full-xml/10.1111/resp.13699_67, https://onlinelibrary.wiley.com/doi/pdf/10.1111/resp.13699_67